Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial

MLA

Boyault, Sandrine, et al. Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial. Jan. 2022. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-22-0371⟩.

APA

Boyault, S., Attignon, V., Soubeyran, I., Morel, A., Tran-Dien, A., Jacquet, A., Dall’Olio, F. G., Jimenez, M., Soria, J.-C., Besse, B., Barlesi, F., Tomasini, P., Karimi, M., Michiels, S., Raimbourg, J., Daniel, C., Janicot, H., Madroszyk, A., Audigier-Valette, C., … Lacroix, L. (2022). Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial. https://doi.org/10.1158/1078-0432.CCR-22-0371⟩

Chicago

Boyault, Sandrine, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall’Olio, et al. 2022. “Comprehensive Genome Profiling in Patients With Metastatic Non-Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial,” January. doi:10.1158/1078-0432.CCR-22-0371⟩.